Jun 16, 2026Metabolic TherapeuticsGLP-1 vs. SGLT2: Which Cardiorenal Benefit Matters Most?GLP-1 receptor agonists and SGLT2 inhibitors can retain benefits together, but kidney, heart-failure, stroke, and MACE evidence differs.glp-1 receptor agonistssglt2 inhibitorscardiorenal outcomesmaceRead article →